|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
New CEO has Work Cut Out as AstraZeneca PLC (AZN) Sales Fall
10/25/2012 7:04:34 AM
AstraZeneca's sales slumped by a bigger-than-expected 19 percent in the third quarter, underscoring the challenges confronting the drugmaker's new chief executive, Pascal Soriot. Faced with patent expiries on once best-selling medicines and a thin pipeline of new drugs, the former Roche executive, who joined on October 1, needs to re-focus operations and step up the hunt for acquisitions, analysts believe. In his first day in office, Soriot suspended the group's share buyback program to increase financial flexibility as the group undergoes a strategy review, which is expected to be presented to investors in the first quarter of 2013. Soriot signaled on Thursday he did not see any dramatic shift away from the current focus on pharmaceutical innovation, rather than diversification, saying his priority was to "restore the company to growth and scientific leadership". That still leaves scope for increased deal-making, however, and bankers have speculated on potential acquisitions ranging from small and mid-sized biotech firms to specialty pharma companies like Forest Laboratories and Shire.
|
|
|
|
|
|
|
|
|
|
|